Sodium polystyrene sulfonate and Ceftazidime drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sodium polystyrene sulfonate (sodium polystyrene sulfonate) and Ceftazidime (ceftazidime). Common drug interactions include anaemia among females and blood creatinine increased among males.

The phase IV clinical study analyzes what interactions people have when they take Sodium polystyrene sulfonate and Ceftazidime. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Sodium polystyrene sulfonate?

Sodium polystyrene sulfonate has active ingredients of sodium polystyrene sulfonate. eHealthMe is studying from 1,667 Sodium polystyrene sulfonate users. Check the latest studies of Sodium polystyrene sulfonate.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

17 people who take Sodium polystyrene sulfonate and Ceftazidime together, and have interactions are studied.

Sodium polystyrene sulfonate and Ceftazidime drug interactions.

What are the common drug interactions of Sodium Polystyrene Sulfonate and Ceftazidime, by gender? *:

female:

Anaemia (lack of blood)
Renal failure acute (rapid kidney dysfunction)
Vomiting
Bacteraemia (presence of bacteria in the blood)
Fall
Influenza like illness
Malaise (a feeling of general discomfort or uneasiness)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Urinary tract infection

male:

Blood creatinine increased
Overdose
Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
Abdominal pain
Abdominal pain upper
Acute respiratory distress syndrome
Anaemia (lack of blood)
Asthenia (weakness)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)

What are the common drug interactions of Sodium Polystyrene Sulfonate and Ceftazidime, by age (0-1 to 60+)? *:

0-1:

Hypopnoea (decrease in the breathing rate)
Overdose

2-9:

n/a

10-19:

Arthralgia (joint pain)
Burning sensation
Muscle spasms (muscle contraction)
Muscular weakness (muscle weakness)
Neuropathy peripheral (surface nerve damage)
Pain in extremity
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)

20-29:

n/a

30-39:

n/a

40-49:

Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Conjunctivitis (pink eye)
Epidermal necrolysis (skin condition that is usually caused by a reaction to drugs)
Multi-organ failure (multisystem organ failure)
Pneumonia
Rash erythematous (redness of the skin)
Sepsis (a severe blood infection that can lead to organ failure and death)

50-59:

Abdominal pain upper
Chronic kidney disease
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)

60+:

Anaemia (lack of blood)
Blood creatinine increased
Acute respiratory distress syndrome
Arthralgia (joint pain)
Asthenia (weakness)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Bacteraemia (presence of bacteria in the blood)
Blood creatine phosphokinase decreased
Blood pressure systolic increased
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)

What are the existing conditions these people have? *

Hyperkalemia (damage to or disease of the kidney): 6 people, 35.29%
Nausea (feeling of having an urge to vomit): 3 people, 17.65%
Constipation: 3 people, 17.65%
Infection: 3 people, 17.65%
Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 3 people, 17.65%
Pain: 3 people, 17.65%
Multiple Myeloma (cancer of the plasma cells): 2 people, 11.76%
Hypotension (abnormally low blood pressure): 2 people, 11.76%
Lung Disorder (lung disease): 2 people, 11.76%
Mucosal Inflammation (infection of mucous membrane): 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Sodium polystyrene sulfonate and Ceftazidime?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously